Patents Assigned to Schering Corporations
  • USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20080145361
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: February 5, 2008
    Publication date: June 19, 2008
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Preparation of powder agglomerate
    Patent number: 7387794
    Abstract: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: June 17, 2008
    Assignee: Schering Corporation
    Inventor: Tsong-Toh Yang
  • Piperazine derivatives useful as CCR5 antagonists
    Patent number: 7384944
    Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: June 10, 2008
    Assignee: Schering Corporation
    Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
  • Piperidine derivatives useful as CCR5 antagonists
    Patent number: 7384948
    Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: June 10, 2008
    Assignee: Schering Corporation
    Inventors: Anandan Palani, Michael W. Miller, Jack D. Scott
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7378518
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: May 27, 2008
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, John W. Clader
  • Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors
    Patent number: 7368457
    Abstract: In an embodiment, this invention discloses novel gamma secretase inhibitors of Formulae I: wherein the various moieties are described herein. Also disclosed is a method of treating Alzheimer's disease using a compound of Formula I or a composition comprising the compound of Formula I.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: May 6, 2008
    Assignee: Schering Corporation
    Inventor: Hubert B. Josien
  • 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine Areceptor antagonists
    Patent number: 7368449
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: May 6, 2008
    Assignee: Schering Corporation
    Inventors: Bernard R. Neustadt, Jinsong Hao, Hong Liu, Craig D. Boyle, Samuel Chackalamannil, Unmesh G. Shah, Andrew Stamford
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7368563
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations iucluding the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: May 6, 2008
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, John W. Clader, Wayne Vaccaro
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7368562
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: May 6, 2008
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, John W. Clader
  • Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7361769
    Abstract: The present invention discloses compounds of formula I wherein m, n, p, R1, R2 and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: April 22, 2008
    Assignee: Schering Corporation
    Inventors: Jing Su, Brian A. McKittrick, Haiqun Tang, Thavalakulamgara K. Sasikumar, Li Qiang
  • Nucleic acids encoding human TNF-? convertase
    Patent number: 7358352
    Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: April 15, 2008
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
  • Uses of IL-174 for treating helminth infections
    Patent number: 7357924
    Abstract: Use of the cytokine designated IL-174 to treat infectious diseases such as helminth infections.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: April 15, 2008
    Assignee: Schering Corporation
    Inventors: Stephen D. Hurst, Sandra M. Zurawski, Donna M. Rennick
  • Compositions comprising viruses and methods for concentrating virus preparations
    Publication number: 20080085545
    Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.
    Type: Application
    Filed: October 24, 2007
    Publication date: April 10, 2008
    Applicant: Schering Corporation
    Inventors: Andreas Frei, Henry Kwan, Varda Sandweiss, Gary Vellekamp, Pui-Ho Yuen, Laureano Bondoc, Fredrick Porter, John Tang, Peter Ihnat
  • Pyrazolotriazines as kinase inhibitors
    Patent number: 7354921
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: April 8, 2008
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch
  • Methods for cancer prognosis and diagnosis
    Patent number: 7354705
    Abstract: The invention provides methods for prognosis and diagnosis in human cancer patients comprising detecting in human tumor tissues the infiltration of certain immune cells associated with poor cancer prognosis. The methods are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: April 8, 2008
    Assignee: Schering Corporation
    Inventors: Jean-Yves Guy Christophe Blay, Isabelle Andrée Lucette Treilleux, Jean-Jacques Pin, Serge Joseph Emma Lebecque
  • Bridged ring NKantagonists
    Patent number: 7354922
    Abstract: A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: April 8, 2008
    Assignee: Schering Corporation
    Inventors: Dong Xiao, Anandan Palani, Cheng Wang, Hon-Chung Tsui, Xianhai Huang, Sapna S. Shah, Ashwin U. Rao, Xiao Chen, Sunil Paliwal, Neng-Yang Shih
  • Use of Pegylated IL-10 to Treat Cancer
    Publication number: 20080081031
    Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
    Type: Application
    Filed: September 27, 2007
    Publication date: April 3, 2008
    Applicant: Schering Corporation
    Inventors: Martin Oft, Catherine Sheppard, John Mumm
  • MCH antagonists for the treatment of obesity
    Patent number: 7348328
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 25, 2008
    Assignee: Schering Corporation
    Inventors: John W. Clader, Anandan Palani, Ruo Xu, Mark D. McBriar, Jing Su, Haiqun Tang
  • MCH antagonists for the treatment of obesity
    Patent number: 7345042
    Abstract: The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: March 18, 2008
    Assignee: Schering Corporation
    Inventors: Anandan Palani, Sherry A. Shapiro, Hubert B. Josien, Thomas A. Bara, John W. Clader, Pradeep B. Pushpavanam, Shengjian Li, Mark D. McBriar
  • Dry Syrup Containing Loratadine
    Publication number: 20080064713
    Abstract: Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 13, 2008
    Applicants: Schering Corporation, Schering-Plough Kabushiki Kaisha
    Inventors: Toshitada Toyoda, Yoshitsugu Muguruma, Yoshitaka Tomoda